Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 4,663 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer

NCT01843673
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
computed tomography, cone-beam computed tomography, radiography, electronic portal imaging, image-guided adaptive radiation therapy
Procedure · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 5:54 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Gene Therapy for IGHMBP2-Related Diseases

NCT05152823
View directory record Official record
Conditions
SMARD1, CMT2S
Interventions
Gene Therapy
Biological
Lead sponsor
Megan Waldrop
Other
Eligibility
2 Months to 14 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

NCT00477269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 22, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Domvanalimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
45
States / cities
Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 22, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00776100
View directory record Official record
Conditions
Lung Cancer
Interventions
clinical observation, radiation therapy
Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
168
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pembrolizumab SC, Pembrolizumab IV, Paclitaxel, Nab-Paclitaxel, Carboplatin, Cisplatin, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Jonesboro, Arkansas • Fullerton, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00740792
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
39
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 22, 2026, 5:54 AM EDT
Withdrawn Phase 3 Interventional

Artificial Neural Network Directed Therapy of Severe Obstructive Sleep Apnea

NCT01286636
View directory record Official record
Conditions
Sleep Apnea
Interventions
computer model, Polysomnogram
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 22, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Birmingham, Alabama • Goodyear, Arizona • Fullerton, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
View directory record Official record
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions
Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 22, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

NCT04488575
View directory record Official record
Conditions
Covid19
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients

NCT00026975
View directory record Official record
Conditions
Laryngeal Cancer
Interventions
Hyperbaric Oxygen
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 22, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction

NCT05257681
View directory record Official record
Conditions
Emphysema or COPD
Interventions
Interlobar fissure completion and pleural adhesiolysis
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 22, 2026, 5:54 AM EDT
Recruiting Phase 1 Interventional

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

NCT07192900
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
Biological · Drug
Lead sponsor
David Bartlett, MD
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

NCT01010971
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

NCT00078312
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Rilvegostomig, Pembrolizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
39
States / cities
La Mesa, California • Los Alamitos, California • Newark, Delaware + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

NCT04348500
View directory record Official record
Conditions
COVID-19
Interventions
Clazakizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 22, 2026, 5:54 AM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 22, 2026, 5:54 AM EDT